On May 13, 2026, Milestone announced financial results for the first quarter ended March 31, 2026. The company reported a net loss of $26.1 million, or $0.20 per share, compared with a net loss of $20.8 million, or $0.31 per share, in the same quarter a year earlier. Although the per-share loss improved year over year, the net loss widened because of higher commercial spending related to the CARDAMYST launch. Milestone Pharmaceuticals Inc. (NASDAQ: MIST) Q1 Earnings Miss: CARDAMYST Launch Begins as Cash Run ...